Are we truly on the brink of a cure for obesity? Or could neglecting the root causes risk worsening the very problems we seek ...

Patients with diabetes who take semaglutide are at increased risk for NAION compared with patients who do not use GLP-1 RAs to control their blood sugar, a new study finds.

Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen ...

A Medicine study used artificial intelligence to discover a naturally occurring molecule, specifically, a peptide, that ...

Fact checked by Nick Blackmer Compounded versions of semaglutide, the active ingredient in weight loss drugs like Ozempic and ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

Proteins in the sheath of cellular protrusions control how effectively cells can adhere to surfaces. Biological cells often ...

Mark Goldston; Executive Chairman of the Board; Beachbody Company Inc. Carl Daikeler; Chief Executive Officer, Director; Bea ...

Patients with diabetes taking a semaglutide medication face a higher risk of NAION, a potentially debilitating ophthalmic condition. Semaglutide medication use is linked with a greater risk of ...